Nixon Gwilt Law

NOVEMBER 14, 2024

In a significant move to incentivize enhanced primary care delivery and management, the Centers for Medicare & Medicaid Services (CMS) have finalized the Advanced Primary Care Management (APCM) codes in the 2025 Medicare Physician Fee Schedule (the” 2025 Final MPFS” or the “Final Rule”).

Physicians 52

Physicians Management Healthcare Healthcare 52

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. Key Strategies for Pharma Marketing in 2025 As pharmaceutical companies look to 2025, embracing a patient-centric approach will be pivotal.

Healthcare 52

Healthcare Healthcare Marketing Pharma 52

Contrarian Sales Techniques

OCTOBER 19, 2024

Malaysia’s Budget 2025 is out, on October 18th 2024, and it’s packed with changes that will touch nearly every aspect of your lives and mine, from salaries to taxes, and even our environment. Now, before you celebrate, this change kicks in February 2025, so we have to wait a bit. Boosting Wages (Finally!) What about you?

Medical sales 52

Medical sales Medical sales reps Government Ethics 52

Nixon Gwilt Law

NOVEMBER 8, 2024

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52

FDA Physicians Management Patients 52

Nixon Gwilt Law

NOVEMBER 8, 2024

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52

FDA Physicians Management Patients 52

Fierce Pharma

AUGUST 7, 2024

Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

FDA 267

FDA Patients 267

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As patients become more digitally savvy, pharma companies are investing in creating seamless digital experiences that cater to their needs and preferences.

Marketing 52

Marketing Healthcare Healthcare Pharma 52

Nixon Gwilt Law

JULY 12, 2024

The 2025 Medicare Physician Fee Schedule Proposed Rule (the “2025 Proposed Rule”) issued by the Centers for Medicare and Medicaid Services (or “CMS”) on July 10, 2024 contains a number of new policy proposals with significant implications for healthcare innovators.

Physicians 52

Physicians Management Food and Drug Administration Healthcare 52

pharmaphorum

AUGUST 24, 2022

The biotech has confirmed it will not launch the biosimilar until March 2025 however, honouring the terms of its 2020 agreement with Alexion that resolved litigation over the validity of patents covering Soliris (eculizumab) in the US.

Safety 88

Safety Sales Patients FDA 88

Pharmaceutical Commerce

AUGUST 8, 2024

Will the looming changes address the concerns of the patient assistance community?

Patients 98

Patients 98

PharmaTimes

MAY 30, 2024

The first phase of the programme will be in place in hospitals across the UK by March 2025

Safety 98

Safety Patients Healthcare Healthcare 98

Nixon Gwilt Law

JULY 23, 2024

In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services. for conditions other than substance abuse disorder, insomnia, and depression)?

Physicians 52

Physicians FDA Safety Management 52

pharmaphorum

OCTOBER 8, 2024

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The The stock rocketed 362% after the announcement, taking Scholar Rock's market cap above $2.7

Sales 102

Sales Marketing Patients 102

Nixon Gwilt Law

JULY 23, 2024

In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services. for conditions other than substance abuse disorder, insomnia, and depression)?

Physicians 52

Physicians FDA Safety Management 52

Prognos Health

NOVEMBER 18, 2021

This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes. More data should uncover more info about the patient. This includes clinical sensors and devices providing patient-generated data. Data key for health equity.

Healthcare 52

Healthcare Healthcare Patients Healthcare Provider 52

MedCity News

JULY 24, 2023

Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025. In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5%

Patients 85

Patients FDA Biopharma 85

European Pharmaceutical Review

FEBRUARY 28, 2024

The implementation of the EU’s Health Technology Assessment Regulation (HTAR) 1 will play a key role in shaping the patient access pathway for ATMPs such as cell and gene therapies. Currently, these therapies primarily target rare or ultra-rare diseases with small patient populations, which therefore limits clinical study sizes.

Patients 97

Patients Ethics Healthcare Healthcare 97

Pharmaceutical Commerce

OCTOBER 10, 2024

The latest news for pharma industry insiders.

Pharma 52

Pharma Patients 52

Pharmaceutical Commerce

JULY 3, 2024

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

FDA 52

FDA Patients 52

MedCity News

JANUARY 16, 2023

A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.

Patients 118

Patients 118

Pharmaceutical Commerce

JUNE 2, 2023

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Patients 98

Patients 98

pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

Prognos Health

NOVEMBER 18, 2021

This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes.

Healthcare 52

Healthcare Healthcare Patients 52

European Pharmaceutical Review

JUNE 10, 2024

“Coupled with the lead-212 production capacity of our research unit in Plano, Texas – the Domestic Distribution & Purification Unit – this new industrial site [in Brownsburg] will enable us to serve North American patients requiring targeted lead-212 radiotherapy treatments,” Guillaume Dureau commented. .

Manufacturing 98

Manufacturing Distribution Pharmaceutical manufacturing Leads 98

World of DTC Marketing

DECEMBER 22, 2020

81 percent of American adults have a smartphone, according to Pew Research but we must remember there is a huge difference between “health (wellness) apps and apps that focus on specific health conditions” The global mHealth app market is growing fast and expected to reach $111 billion by 2025. Sleep monitoring.

Pharma 230

Pharma Doctors Patients Management 230

MedCity News

MARCH 28, 2023

Aneesh Chopra, president and co-founder of CareJourney, predicted accelerated enrollment in value-based care models in 2024 and 2025.

Healthcare 94

Healthcare Healthcare Doctors Patients 94

Pharmacy Times

OCTOBER 1, 2024

Approximately 75% of adults trust their physicians, nurses, and pharmacists either a great deal or a lot, highlighting the importance of pharmacists for patient education.

Physicians 29

Physicians Education Patients 29

Penrod

JANUARY 12, 2024

Additionally, OCR specifies that when a healthcare entity subject to HIPAA collects such information, like when a potential patient seeks services in their area, that data is classified as Protected Health Information (PHI). The post Patient Privacy in 2024 appeared first on Penrod.

Patients 52

Patients Healthcare Provider Healthcare Healthcare 52

Pharmacy Times

OCTOBER 7, 2024

The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks.

Patients 29

Patients 29

European Pharmaceutical Review

OCTOBER 22, 2024

The UK is set to be the first country to introduce a new regulatory framework for innovative products manufactured at or close to the point of patient care, says the Medicines and Healthcare products Regulatory Agency (MHRA). The agency anticipated that the regulation could become law in Summer 2025.

Medicine 52

Medicine Manufacturing Safety Consulting 52

Pharma Marketing Network

NOVEMBER 15, 2024

Table of Contents Sr# Headings 1 Know Your Audience and Their Needs 2 Leverage Branded and Unbranded Content 3 Engage Responsibly and Transparently 4 Utilize Influencers and Patient Stories 5 Analyze and Optimize Regularly 1. Are you trying to engage healthcare professionals (HCPs), patients, or caregivers?

Media 52

Media Pharma Marketing Medical 52

European Pharmaceutical Review

OCTOBER 17, 2024

These factors may increase the likelihood that patients and caregivers carry it regularly. Thus, ARS Pharmaceuticals anticipates approval by Q1 2025 in the UK and launch by summer 2025. What is significant about approval of EURneffy as the first new delivery method in over three decades for adrenaline?

Food and Drug Administration 121

Food and Drug Administration Medicine Consulting Food 121

European Pharmaceutical Review

OCTOBER 31, 2024

Supported through £16 million in funding, a programme helping SME manufacturers to adopt technology and digital skills is set to persist into 2025 and expand into all regions of England, according to the Made Smarter Adoption programme.

Manufacturing 52

Manufacturing Medical science Medicine Engineering 52

European Pharmaceutical Review

JUNE 13, 2024

Significant reductions of treated bleeding episodes in haemophilia A In the FRONTIER 2 trial, treatment once-weekly and once-monthly with Mim8 provided a 97 percent and 99 percent reduction in treated bleeds in patients with no prior prophylaxis treatment, respectively. This was compared to prior coagulation factor prophylaxis.

Safety 98

Safety Patients Pharmaceutical 98

European Pharmaceutical Review

FEBRUARY 2, 2024

So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

European Pharmaceutical Review

NOVEMBER 21, 2023

According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler. Dosing of first patients is planned in the first half of 2024. However, this accounts for nearly half of GSK’s carbon footprint, and contributes to the carbon footprint of global health systems.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

European Pharmaceutical Review

AUGUST 1, 2022

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.

Medicine 105

Medicine Networking Electronics Healthcare 105